Clinical TrialsSearch results
Number of results: 68732
Completed
- A Phase III Study of Docetaxel/S-1 versus S-1 in the Treatment of Curatively Resected Stage III Gastric Cancer
- Gastric Cancer
- KODERA Yasuhiro
- 2019-03-29
Completed
- A phase III study of FPF3401
- Hyposelenemia
- Urabe Hiromi
- 2022-07-09
Completed
- A Phase III study of M121101 in patients with pincer nail
- Pincer nail
- Nishiura Tomoyuki
- 2020-12-24
Completed
- A Phase III Study of SCD411 in Subjects with Neovascular Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Sakamoto Taiji
- 2021-04-16
Completed
- A Phase III study to evaluate the efficacy and safety of NRL-1 intranasally administered in Japanese pediatric patients with status epilepticus
- Japanese pediatric patients with status epilepticus or with seizures that may progress to status epi
- Nakagawa Eiji
- 2022-08-11
Completed
- A Phase III study to evaluate the Efficacy, Safety, and Antiviral Activity of RO7496998 (AT-527) in Non-hospitalized Patients with Mild or Moderate COVID-19
- SARS-COV-2 infection
- Rebecca Saenz, M.D., Ph.D.
- 2021-05-07
Completed
- A phase III, randomized, active-comparator, non-inferiority study to demonstrate the Immunogenicity and Safety of DS-5670a in children 12 through 17 years of age.
- Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)
- Inoguchi Akihiro
- 2022-10-20
Completed
- A phase III, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy and safety of M605108 in patients with acne vulgaris
- Acne vulgaris
- Nishiura Tomoyuki
- 2020-12-16
Completed
- A phase3b study of KTE-C19 (at the time of manufacture of commercially available products) in patients with the indication on the package insert
- DLBCL, PMBCL, TFL, HGBCL
- Aso Hiroya
- 2021-05-11
Completed
- A pilot open-label clinical trial to evaluate decrease of brain amyloid beta(A-beta) by removing blood AB
- Alzheimer's Disease, Mild Cognitive Impairment due to AD
- Yuzawa Yukio
- 2019-03-29